Hisun Pharmaceutical Marks Seven Decades of Global Expansion in Milan

The gathering in Milan brought together representatives from the Chinese Consulate, international business associations, and major global pharmaceutical firms to discuss the future of cross-border cooperation. For Hisun, the evening served as more than a celebration; it highlighted a transition toward its 'Internationalization 2.0 Strategy.' Launched in 2025, this initiative shifts the focus from traditional API exports toward deeper integration in overseas markets, including joint research, technology transfers, and local manufacturing partnerships within Europe.

Since its founding in 1956, Hisun has consistently navigated global regulatory landscapes, becoming one of the first Chinese firms to secure U.S. FDA approval for its products in 1992. Today, the company operates in over 100 countries, maintaining EU GMP certification for its manufacturing facilities. By showcasing the industrial vitality of Taizhou—often cited as the 'Pharmaceutical Capital of China'—the company aims to solidify its position as a key partner for European pharmaceutical entities, moving beyond simple supply chains into collaborative R&D and regulated market development.